Hepatitis C elimination - Macro-elimination

被引:8
作者
Kaberg, Martin [1 ,2 ]
Weiland, Ola [1 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden
[2] Stockholm Ctr Dependency Disorders, Stockholm Needle Exchange, Stockholm, Sweden
关键词
HCV; HCV care cascade; HCV screening; macro-elimination; INJECTING DRUG-USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; PEOPLE; INTERVENTIONS; METAANALYSIS; PREVENT; CARE; TRANSMISSION; PREVALENCE; INFECTION;
D O I
10.1111/liv.14352
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In 2016 the WHO set a goal to obtain an 80% reduction in new chronic HCV cases, requiring a level of diagnosis of 90%, treatment coverage of 80% and resulting in a 65% reduction in HCV-related deaths by 2030. This goal is easier to reach in specific populations such as people who inject drugs (PWID), men who have sex with men (MSM) or blood-transfusion recipients before screening for HCV became mandatory and in high-income regions. It is much more difficult to achieve macro-elimination throughout the population especially in low-income areas with underdeveloped infrastructures, a high prevalence of HCV and limited economic resources. To achieve the WHO goals by 2030, awareness of HCV must increase and the cascade of care must be improved and implemented. Diagnostic procedures and treatment should be affordable and universally available. At the end of 2017 fewer than 15 countries were on track to reach these goals by 2030.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 41 条
[1]   Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia [J].
Alavi, Maryam ;
Law, Matthew G. ;
Valerio, Heather ;
Grebely, Jason ;
Amin, Janaki ;
Hajarizadeh, Behzad ;
Selvey, Christine ;
George, Jacob ;
Dore, Gregory J. .
JOURNAL OF HEPATOLOGY, 2019, 71 (02) :281-288
[2]  
[Anonymous], 2017, COUNTR TRACK EL HCV
[3]  
[Anonymous], 2018, JUST 12 COUNTR WORLD
[4]  
[Anonymous], 2021, GLOB PROGR REP HIV V
[5]  
[Anonymous], ELIMINATING VIRL HEP
[6]   Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention [J].
Ayoub, H. H. ;
Abu-Raddad, L. J. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (06) :486-495
[7]   Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review [J].
Bajis, Sahar ;
Dore, Gregory J. ;
Hajarizadeh, Behzad ;
Cunningham, Evan B. ;
Maher, Lisa ;
Grebely, Jason .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 47 :34-46
[8]   Is global elimination of HCV realistic? [J].
Calvaruso, Vincenza ;
Petta, Salvatore ;
Craxi, Antonio .
LIVER INTERNATIONAL, 2018, 38 :40-46
[9]   Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing [J].
Corson, Stephen ;
Greenhalgh, David ;
Taylor, Avril ;
Palmateer, Norah ;
Goldberg, David ;
Hutchinson, Sharon .
DRUG AND ALCOHOL DEPENDENCE, 2013, 133 (01) :172-179
[10]   The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA [J].
Coyle, Catelyn ;
Moorman, Anne C. ;
Bartholomew, Tyler ;
Klein, Gary ;
Kwakwa, Helena ;
Mehta, Shruti H. ;
Holtzman, Deborah .
HEPATOLOGY, 2019, 70 (02) :476-486